Last reviewed · How we verify
AZD2287
At a glance
| Generic name | AZD2287 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer (PHASE1)
- Study of AZD0754 in Participants With Metastatic Prostate Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD2287 CI brief — competitive landscape report
- AZD2287 updates RSS · CI watch RSS
- AstraZeneca portfolio CI